Back to search

University of British Columbia

Development of an optimized liposomal formulation of a camptothecin to improve treatment of neuroblastoma

Abstract

dc:description

Purpose: To develop an optimized liposomal formulation of topotecan for use in the treatment of patients with neuroblastoma. Experimental design: Cytotoxic activity of both camptothecins (topotecan (Hycamtin) and irinotecan (Camptosar)) was determined against SK-N-SH; IMR-32 and LAN-1 neuroblastoma cell lines. Sphingomyelin (SM)/Cholesterol (Chol) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/Chol liposomes were prepared using extrusion methods and then loaded with topotecan using a method that relies on copper-drug complexation in combination with a transmembrane pH gradient. The influence of lipid composition and encapsulated drug-to-lipid ratio was assessed in-vitro in the presence and absence of serum. Dose-range finding studies were used to define maximum tolerated dose of the optimized liposomal formulation. Pharmacokinetic studies were completed to compare plasma elimination of topotecan following intravenous administration of the liposomal formulation or the currently used clinical product (Hycamtin). Studies were done in NRG mice bearing established subcutaneous tumours. The anti-tumour activity of the liposomal formulation was compared to Hycamtin when administered to NRG mice with established neuroblastoma tumours. Results: Topotecan was significantly more effective than irinotecan when used to treat neuroblastoma cell lines (as determined by IC50). Increased exposure time to topotecan further increased the drug potency against all neuroblastoma cell lines. In vitro studies showed that SM/Chol liposomes retained topotecan better than DSPC/Chol liposomes. Decreasing the drug-to-lipid ratio from 0.1 to 0.025(mol: mol) engendered significant increase in drug retention. The optimized SM/Chol liposomal topotecan formulation exhibited a 10-fold increase in plasma half-life and a 1000-fold increase in AUC0-24h when compared to Hycamtin administered at equivalent doses. When administered at 5mg/kg, SM/Chol liposomal topotecan was significantly more effective than Hycamtin administered at 2-times the dose. The liposomal formulation increased the life span of mice by 50% for the systemic tumour model and by 87% for the subcutaneous models. Conclusion: Increased systemic drug exposure following administration of the optimized SM/Chol liposomal topotecan formulation produced superior response in subcutaneous and systemic models of neuroblastoma. In the future, this formulation will be assessed in combination with radiotherapy and immunotherapy treatment modalities currently used in neuroblastoma therapy.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Pathology and Laboratory Medicine
Grantor dc:publisher
University of British Columbia
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chernov, Alina

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/58465

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Chernov, Alina. Development of an optimized liposomal formulation of a camptothecin to improve treatment of neuroblastoma. master's thesis, University of British Columbia, 2016. http://hdl.handle.net/2429/58465